Anlotinib Offers Efficacy Across Subtypes of Soft-Tissue Sarcoma
A phase II trial showed that the tyrosine kinase inhibitor anlotinib has promising efficacy across a variety of subtypes of advanced refractory soft-tissue sarcoma.
Quality of Life Could Help Select Treatment for Soft-Tissue Sarcoma
Understanding quality of life and the detrimental impact of disease progression is critical for long-term care and survival of patients with soft-tissue sarcoma.
Gemcitabine Plus Pazopanib Shows Promise in Soft-Tissue Sarcomas
Combined therapy with gemcitabine and pazopanib appears to be a viable treatment option for patients with soft-tissue sarcomas refractory to anthracycline or ifosfamide.
Regorafenib Ups Progression-Free Survival in Several Soft-Tissue Sarcomas
Regorafenib is associated with improved progression-free survival in pretreated patients with advanced refractory non-liposarcoma soft-tissue sarcomas.
Busulfan/Melphalan Associated With Longer Survival in High-Risk Ewing Sarcoma
Busulfan/melphalan high-dose chemotherapy consolidation is associated with better survival vs VAI among patients with localized high-risk Ewing sarcoma.
By clicking Accept, you agree to become a member of the UBM Medica Community.